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Objective: To identify at species level, in a prospective study in a tertiary university hospital during the two years 1996 
and 1997, all isolates of Campylobacferspp. and related organisms and to determine their susceptibility to erythromycin 
and ciprofloxacin. 
Methods: The feces were collected in Caw-Blair medium, and isolation was performed on Karmali agar incubated at 
35°C. BACTEC Plus aerobic/f vials were used for blood cultures. Identification was performed by biochemical methods 
for Campylobacter jejuni and by molecular hybridization for the other species. MlCs for erythromycin and ciprofloxacin 
were determined by Etest. 
Result.: In total, 142 isolates from 140 infected patients, including 135 fecal isolates and seven blood isolates, were 
analyzed. Clinical findings of the seven patients with bacteremia and the seven patients with gastroenteritis due to 
species other than Campylobacfer jejuni or Campylobacter coli showed a predominance of immunocompromised 
patients. The fecal isolates include 113 (83.7%) Campylobacfer jejuni, nine (6.6%) Campylobacter coli, four Arcobacter 
butzleri, two Campylobacter fetus and one Helicobacter pullorum. Of the seven isolates from blood culture. three were 
Campylobacter jejuni, three Campylobacter fetus and one Helicobacter cinaedi. Resistance to ciprofloxacin (MIC >4 mgk) 
was reported for 18 (1 5.6%) Campylobacfer jejuni isolates, three Campylobacfer coli isolates, one Campylobacter fetus 
isolate and one Arcobacfer bufzleri isolate. Resistance to erythromycin (MIC >8 mgL) was found for two isolates of 
Campylobacter coli, which were also resistant to ciprofloxacin, and the isolate of Helicobacter cinaedi. 
Conclusions: This study reports a predominance of Campylobacfer jejuni from stools, but a variety of more rarely 
isolated species was found in immunocompromised patients, emphasizing the necessity to identify fecal as well as blood 
isolates to the species level. Antimicrobial susceptibility tests to major antibiotics active against campylobacteria should 
be done routinely to follow the rate of resistance. 
Key words: Campylobacter, Arcobacfer, Helicobacter, identification, antimicrobial susceptibility 
INTRODUCTION 
Campylobacter spp. represent the leading cause of acute 
bacterial diarrhea in developed countries [1,2]. The 
predominant species is Campylobacter jejuni, followed 
by C. coli [1,3]. Extraintestinal infections such as 
bacteremia occur more rarely, mainly in immuno- 
Corresponding author and reprint requests: 
Nadia Liassine, Central Laboratory of Bacteriology, 
University Hospital, 25 rue Micheli-du-Crest, 
1211 Geneva 4, Switzerland 
Tel: +41 22 372 73 09 Fax: +41 22 372 73 04 
E-mail: Nadia.Liassine@hcuge.ch 
Accepted 27 April 1999 
compromised patients, and are due to various species of 
Campylobacter and related organisms [3,4]. 
During the last decade, the taxonomy of Cumpylo- 
bacter spp. and related organisms has been extensively 
revised and, based on molecular data, it now includes 
the genera Campylobacter, Arcobacter and Helicobacter 
(5,6]. Campylobacters are fastidious microorganisms, 
and complete identification to species level is rarely 
performed in microbiology laboratories, where they 
are frequently reported as ' Campylobacter jejuni/colr". 
Thus the incidence and clinical si@cance of newly 
described species of Campylobacter and related organ- 
isms remain largely unknown. 
The treatment of choice for infections with C. 
jejuni and C. coli includes erythromycin or fluoro- 
quinolones [3]. Fluoroquinolones are often given 
empirically to treat suspected gastroenteritis because 
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they are active against all of the main enteric pathogens. 
In recent years, the emergence and spread of resistance 
in campylobacters, mainly to fluoroquinolones r/-121 
but also to macrolides [9,11,13-151, has been reported 
in different countries. 
The aim of the present prospective study was 
twofold. First, all campylobacters and related organisms 
isolated h m  stools or blood during the two years 1996 
and 1997 were identified to species level by phenotypic 
and genotypic methods, in order to assess their 
occurrence and clinical significance. Second, their 
susceptibility to erythromycin and ciprofloxacin was 
determined to estimate the prevalence of clinically 
significant resistance and to evaluate current thera- 
peutic recommendations. 
MATERIALS AND METHODS 
Patients 
The university hospital of Geneva is a 1300-bed 
healthcare center providing primary and tertiary care 
for Geneva and the surrounding area. The detection of 
Campylobacter spp. was performed systematically for all 
patients for whom a bacterial analysis of feces was 
requested. 
Specimens and culture 
Stools were collected in a receptacle containing 
Cary-Blair transport medium. Primary plating was 
made on Campylobacter selective medium (Karmali; 
Oxoid, Basingstoke, UK) [16]. Blood cultures were 
performed in BACTEC Plus aerobic/F vials and 
incubated in the BACTEC 9240 (Becton Dickinson 
Diagnostic Instrument Systems, Sparks, Md, USA). For 
the positive blood cultures with a typical morphology 
on Gram and acridme staining (S-shaped rods), 
subsequent isolation was performed on non-selective 
blood agar incubated in a micro-aerophilic atmosphere 
(Generbox Microaer, bioMCrieux, Marcy l’Etoile, 
France) at 35°C for 48 h. 
Phenotypic identification 
The oxidase test and Gram stain were performed on all 
suspected colonies. Identification was completed by the 
catalase test, hippurate hydrolysis test [17], indoxyl 
acetate hydrolysis test (disk method) [18], and 
susceptibility to polymyxin B [19]. The reference 
strains of C. jejuni NCTC 11351, C. coli LMG 6440 
and C.fetus subspeciefetus ATCC 27374 were used as 
controls. Isolates with a positive hippurate hydrolysis 
and catalase reaction were reported as C. jejuni. All 
other isolates were identified by dot-blot DNA hybri- 
dization. 
Dot-blot DNA hybridization 
This was performed as described previously [20]. 
Briefly, genomic DNA was extracted &om clinical 
isolates by &ne lysis and spotted onto filters. The 
filters were then hybridued under stringent conditions 
with digoxigenin-labeled genomic DNA of the corres- 
ponding type strains, and the resulting hybrids were 
detected by the chromogenic alkaline phosphatase 
protocol proposed by the manufacturer (Boehringer 
Mannheim, Mannheim, Germany). 
Antimicrobial susceptibilii testing 
MICs of erythromycin and ciprofloxacin were 
determined by Etest (AB Biodisk, Solna, Sweden) on 
Mueller-Hinton agar with 5% sheep blood [21,22]. 
The inoculum was adjusted to the turbidity of a 0.5 
McFarland standard, and plates were incubated in a 
micro-aerophilic atmosphere at 35OC for 24 h. Isolates 
were considered susceptible if the respective MIC 
values were 1 8  mg/L for erythromycin and (4  mg/L 
for ciprofloxacin [I 13. 
RESULTS 
During the two years 1996 and 1997,140 patients were 
found to be infected by Campylobacter spp. or related 
organisms, including 133 patients with gastroenteritis 
and seven patients with bacteremia. Detailed clinical 
findings of patients with bacteremia and those with 
gastroenteritis due to species other than C. jejuni and 
C. coli are summarized in Table 1. Of the 140 patients, 
60 (42.9%) were female. The mean age of patients with 
gastroenteritis was 29.8 years (range: 40 days to 94 
years), and that for patients with bacteremia was 57.7 
years (range: 25-86 years). Children below the age of 
16 years represented one-third (47 patients) of 
the patients infected by campylobacters. The peak 
incidence was observed during the 4 months of June 
to September, representing 69 (49%) of the infected 
patients. Five of the seven cases with bacteremia 
occurred during the summer. Of the seven patients 
with gastroenteritis due to species other than C. jejuni 
or C. coli, five were irnmunocompromised and three 
(one Arcobactw butzleri, one C. fetus, one Helicobacter 
pullorurn) were acquired during the hospital stay. Three 
of the seven bacteremias (two C. fetus, one C. jejuni) 
were also acquired during the hospital stay. In total, 142 
isolates, including 135 fecal isolates and seven blood 
isolates, were analyzed. For one patient, C. jejuni was 
isolated from both feces and blood. Another patient 
with gastroenteritis was concomitantly infected by C. 
jejuni and C. coli. The results of identification and the 
detailed results of biochemical tests are presented in 
Table 2. All isolates in the present study were oxidase 
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Table 2 Distribution and results of identification tests of Campyfobucter spp. and related organism isolated during the 2 years 
1996 and 1997 
Identification tests 
Polymyxin Hip p u rat e Indoxyl 
Specimen Catalase susceptibility hydrolysis acetate hydrolysis 
Total 
number Stool Blood + - or (+) Susceptible Resistant + - + -  
Campylobader jejuni 116 113 3 116 116 113 3 3/3b 
C. coli 9 9 9 9 9 9 
C. fetus 5 2 3 5 5 5 5 
Arcobacter butzlm' 4 4 4 4 4 4 
Helicobacter cinaedi 1 1 1 1 1 1 
H .  pulZorum 1 1 1 1 1 1 
Campylobader spp.' 6 6 
'Not further idended (isolates lost during subculturing). 
+, positive test; (+), weakly positive test; -, negative test. 
three isolates tested (isolates with negative hippurate hydrolysis test). 
Table 3 MICs of ciprofloxacin and erythromycin of 135 isolates of Campylobwter spp. and related organisms 
MICs (mg/L) 
Antibiotic Species n 0.03 0.06 0.12 0.25 0.5 1 2 4 6 8 16 232 Range 
~~ ~ ~~~ 
Cipmfloxacin Campylobacfer jejuni 
C .  coli 
Arcobacter butzhi  
Helicobacter cinaedi 
H .  pullorum 
c .  fetus 
Erythromycin C .  jejuni 
C .  coli 
C .  fetus 
A .  butzleri 
H .  cinaedi 
H .  pullorum 
115 5 38 23 16 8 6 1 
9 2  2 1  1 
5 1 1 2  1 
4 1 1 1  
1 1  
1 -  1 
115 1 3 28 39 33 8 3 
9 1  1 2 2 1  
5 1 3 1  
4 3 1 
1 
1 1 
18 0.03 to 232 
3 0.03 to 232 
0.25-6 
1 0.12 to 232 
0.03 
0.12 
0.12-6 
2 0.03 to 232 
1-4 
4-8 
1 132 
2 
Numbers in bold indicate resistant isolates. 
positive. In Gram-staining, the four isolates of A. 
butzleri appeared to be less curved than Cumpylobarter 
spp. Three hippurate-negative Cumpylobucter isolates 
were identified as C. jejuni by DNA hybridization; the 
identity was further confirmed by a positive hybridi- 
zation signal on Southern blots with a probe for the 
hippuricase gene [23] (data not shown). 
Antimicrobial susceptibility 
The distribution of MICs for ciprofloxacin and 
erythromycin is presented in Table 3. High-level 
resistance to ciprofloxacin (MIC 132  mg/L) was 
reported for 18 (15.6%) C. jejuni isolates, three (33.3%) 
C. coli isolates and one A. butzlm' isolate, and low-level 
resistance (MIC=6 mg/L) for one isolate of C. fetus. 
Resistance to erythromycin (MIC 232 mg/L) was 
observed in two (22.2%) isolates of C. coli which were 
also resistant to ciprofloxacin, and in the single isolate 
of H. cinaedi. Among the erythromycin-susceptible 
isolates, the mean MIC of erythromycin for A.  butzlm' 
(4 mg/L) was higher than that for C. jejuni (1 mg/L) 
and C.fetus (2 mg/L). 
DISCUSSION 
Campylobacters cause both diarrheal and systemic 
illnesses and represent the most common bacterial 
cause of gastroenteritis in developed countries [1,2]. 
C. jejuni is the predominant species, as observed also in 
the present study, but other more rarely isolated species 
are involved, particularly in patients with underlying 
conditions such as malignancy, diabetes mellitus, liver 
cirrhosis and immunosuppression [3,4]. In these patients, 
campylobacter infections can be hospital acquired [4]. 
Although C. fetus has long been considered to be the 
prototype of bacteremia in relation to its endovascular 
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tropism [24], our results report equal numbers ofbactere- 
mia due to C. jejuni as to C.fetus, as previously reported 
by othm [4]. Bacteremia due to campylobacters includes 
both transient bacteremia in a normal host with acute 
campylobacter enteritis, and sustained bacteremia, 
particularly in a compromised host [3,4]. The sustained 
bacteremia due to H .  cinaedi observed in this study in 
an immunocompetent HIV-negative patient with 
febrile gastroenteritis contrasts with the cases in the 
literature, mainly described in HIV-infected homo- 
sexual patients, where it causes proctocolitis, colitis and 
bacteremia [3]. Little is known of the pathogenicity of 
another Helicobacter sp., H. pullorurn, found in one 
severely immunocompromised patient in the present 
study, although gastroenteritis has been previously 
reported [25]. Of the four gastroenteritis episodes due 
to A. htzleri reported in this study, two occurred in 
immunocompromised patients and two in young 
adults who had traveled, suggesting that this recently 
described pathogen has a worldwide distribution. A. 
butzleri was isolated as the only bacterial enteric 
pathogen, with the exception of a patient fbm Cape 
Verde Islands co-infected by Vibrio cholerue 0 1 .  These 
fin+ confirm the gastrointestinal pathogenicity of 
A. bu t zh '  [6,26]. 
The isolates of C. fetus, Helicobacter. spp. and A. 
butrlm' do not grow at 42OC [6,27], a temperature 
fiequently used in microbiology laboratories for 
isolation of campylobacters fipm stools. This may 
explain the underestimation of these species by routine 
microbiology laboratories. We never reported A. 
butzlm' or C. fetus fipm stools when we used a 
tempera- of 42OC instead of 35OC for isolation of 
campylobacters, prior to this study [28]. It is well 
recognized now that phenotypic methods do not allow 
accurate identification of all  campylobacters, and that 
the genetic methods, such as nucleic acid probes, 
represent a powerful identification tool [27]. As 
genotypic methods are not routinely used in clinical 
microbiology laboratories, we recommend the strategy 
of identification applied in the present study, in which 
phenotypic methods represent the first-line measure 
and genotypic methods are used for definitive identi- 
fication of all campylobacters. Primarily, we used 
phenotypic characterization with Gram-staining 
(ArcobaEter spp. are less curved than Campylobucter), basic 
phenotypic tests such as oxidase and catalase (Atwbacter 
spp. have a negative or weakly positive catalase test), 
susceptibility to polymyxin B (ffeluobacter spp. except 
for H. pullorurn were resistant to polymyxin B) and the 
hippurate hydrolysis test. The hippurate hydrolysis test 
performed in standardized conditions and concomi- 
tantly with reference strains is a reliable method [27l 
which allows identification of C. jguni, the only species 
with a positive test. Although we have obtained 
reproducible results with the indoxyl acetate hydrolysis 
test, this test failed to distinguish hippurate-negative C. 
jejuni fbm C. coli strains, or H. pullorurn b m  C. mli. 
The determination of nalidixic acid resistance is not 
recommended as an identification characteristic, because 
of the increasing ficquency of acquired quinolone 
resistance in campylobacters [29]. We applied geno- 
typic methods only for isolates with a negative 
hippurate hydrolysis test, i.e. less than 20% of isolates, 
with highly specific results. Routine microbiology 
laboratories which cannot apply genomic methods 
should send all the isolates of campylobacters with a 
negative hippurate hydrolysis test to a reference center 
for definitive identification. This scheme allows efficient 
identification of all campylobacters, including the rare 
isolates of C. jejuni with a negative hippurate hydrolysis 
test [27,30], and will allow a better understanding 
of the pathogenicity and epidemiology of campylo- 
bacters. 
The determination of the antimicrobial suscepti- 
bility of campylobacters can be easily performed by 
Etest in routine laboratories [21,22,31]. The deter- 
mination of MICs allows comparison of results fbm 
Merent studies, even if the applied breakpoints are 
Merent fipm one study to another in relation to the 
lack of specific recommendations for campylobacters 
by the NCCLS [32]. In the present study, 15% of C. 
jejwni were found to be resistant to fluoroquinolones, a 
rate higher than the 3% of quinolone resistance 
reported in Switzerland in 1990 by Adler-Mosca and 
Altwegg [7], but lower than those reported elsewhere. 
In Spain, up to 50% of campylobacters were resistant 
to fluoroquinolones [14], and in Thailand an explosive 
increase was noted, with 84% of campylobacters 
found to be resistant to fluoroquinolones and 15% to 
macrolides [9]. The development of antimicrobial 
resistance of campylobacters varies fbm one country to 
another and may be linked to the use of antimicrobial 
agents in human and veterinary medicine [33]. In 
Switzerland, a recent study [34] reported a low rate of 
quinolone resistance among veterinary isolates of 
campylobacters (4%); this may be related to the limited 
veterinary use of quinolones. In human medicine, 
although the majority of cases of gastroenteritis due to 
Carnpylobacter do not require specific antimicrobial 
treatment, antimicrobial therapy is necessary for severe 
enterocolitis and extraintestinal manifestations [3]. It is 
based on macrolides or fluoroquinolones and is often 
started on an empirical basis, because the result of 
antimicrobial susceptibility is generally obtained afier 
the beginning of therapy. In these circumstances, the 
choice of antimicrobial agent should be based on the 
susceptibility pattern of a given counq. 
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In conclusion, microbiology laboratories must 
detect and accurately identify campylobacters, the 
leading cause of gastroenteritis and potential invasive 
pathogens in immunocompromised patients. The 
routine identification of C. jejuni at the species level is 
accessible for clinical microbiology laboratories, but the 
other species require genotypic methods. The determin- 
ation of antimicrobial susceptibility of campylobacters is 
easily performed by the Etest and is useful for both 
clinicians and surveillance of antimicrobial resistance. 
' 
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